Advanced glycation end products, oxidation products, and the extent of atherosclerosis during the VA diabetes trial and follow-up study

Aramesh Saremi, Scott Howell, Dawn C. Schwenke, Gideon Bahn, Paul J. Beisswenger, Peter D. Reaven

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

OBJECTIVE To determine whether plasma levels of advanced glycation end products and oxidation products play a role in the development of atherosclerosis in patients with type 2 diabetes (T2D) over nearly 10 years of the VA Diabetes Trial and Follow-up Study. RESEARCH DESIGN AND METHODS Baseline plasma levels of methylglyoxal hydroimidazolone, N∞-carboxymethyl lysine, N∞-carboxyethyl lysine (CEL), 3-deoxyglucosone hydroimidazolone and glyoxal hydroimidazolone (G-H1), 2-aminoadipic acid (2-AAA), and methionine sulfoxide were measured in a total of 411 participants, who underwent ultrasound assessment of carotid intima-media thickness (CIMT), and computed tomography scanning of coronary artery calcification (CAC) and abdominal aortic artery calcification (AAC) after an average of 10 years of follow-up. RESULTS In risk factor-adjustedmultivariable regressionmodels, G-H1was associated with the extent of CIMT and CAC. In addition, 2-AAA was strongly associated with the extent of CAC, and CEL was strongly associated with the extent of AAC. The combination of specific advanced glycation end products and oxidation products (G-H1 and 2-AAA) was strongly associated with all measures of subclinical atherosclerosis. CONCLUSIONS Specific advanced glycation end products and metabolic oxidation products are associated with the severity of subclinical atherosclerosis over the long term and may play an important role in the "negative metabolicmemory" of macrovascular complications in people with long-standing T2D.

Original languageEnglish (US)
Pages (from-to)591-598
Number of pages8
JournalDiabetes Care
Volume40
Issue number4
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

2-Aminoadipic Acid
Advanced Glycosylation End Products
Atherosclerosis
Coronary Vessels
Carotid Intima-Media Thickness
Type 2 Diabetes Mellitus
Lysine
Arteries
Glyoxal
Pyruvaldehyde
Tomography
imidazolone

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Advanced glycation end products, oxidation products, and the extent of atherosclerosis during the VA diabetes trial and follow-up study. / Saremi, Aramesh; Howell, Scott; Schwenke, Dawn C.; Bahn, Gideon; Beisswenger, Paul J.; Reaven, Peter D.

In: Diabetes Care, Vol. 40, No. 4, 01.04.2017, p. 591-598.

Research output: Contribution to journalArticle

Saremi, Aramesh ; Howell, Scott ; Schwenke, Dawn C. ; Bahn, Gideon ; Beisswenger, Paul J. ; Reaven, Peter D. / Advanced glycation end products, oxidation products, and the extent of atherosclerosis during the VA diabetes trial and follow-up study. In: Diabetes Care. 2017 ; Vol. 40, No. 4. pp. 591-598.
@article{49ca705a104c46b882d0ca2298a7eba6,
title = "Advanced glycation end products, oxidation products, and the extent of atherosclerosis during the VA diabetes trial and follow-up study",
abstract = "OBJECTIVE To determine whether plasma levels of advanced glycation end products and oxidation products play a role in the development of atherosclerosis in patients with type 2 diabetes (T2D) over nearly 10 years of the VA Diabetes Trial and Follow-up Study. RESEARCH DESIGN AND METHODS Baseline plasma levels of methylglyoxal hydroimidazolone, N∞-carboxymethyl lysine, N∞-carboxyethyl lysine (CEL), 3-deoxyglucosone hydroimidazolone and glyoxal hydroimidazolone (G-H1), 2-aminoadipic acid (2-AAA), and methionine sulfoxide were measured in a total of 411 participants, who underwent ultrasound assessment of carotid intima-media thickness (CIMT), and computed tomography scanning of coronary artery calcification (CAC) and abdominal aortic artery calcification (AAC) after an average of 10 years of follow-up. RESULTS In risk factor-adjustedmultivariable regressionmodels, G-H1was associated with the extent of CIMT and CAC. In addition, 2-AAA was strongly associated with the extent of CAC, and CEL was strongly associated with the extent of AAC. The combination of specific advanced glycation end products and oxidation products (G-H1 and 2-AAA) was strongly associated with all measures of subclinical atherosclerosis. CONCLUSIONS Specific advanced glycation end products and metabolic oxidation products are associated with the severity of subclinical atherosclerosis over the long term and may play an important role in the {"}negative metabolicmemory{"} of macrovascular complications in people with long-standing T2D.",
author = "Aramesh Saremi and Scott Howell and Schwenke, {Dawn C.} and Gideon Bahn and Beisswenger, {Paul J.} and Reaven, {Peter D.}",
year = "2017",
month = "4",
day = "1",
doi = "10.2337/dc16-1875",
language = "English (US)",
volume = "40",
pages = "591--598",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Advanced glycation end products, oxidation products, and the extent of atherosclerosis during the VA diabetes trial and follow-up study

AU - Saremi, Aramesh

AU - Howell, Scott

AU - Schwenke, Dawn C.

AU - Bahn, Gideon

AU - Beisswenger, Paul J.

AU - Reaven, Peter D.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - OBJECTIVE To determine whether plasma levels of advanced glycation end products and oxidation products play a role in the development of atherosclerosis in patients with type 2 diabetes (T2D) over nearly 10 years of the VA Diabetes Trial and Follow-up Study. RESEARCH DESIGN AND METHODS Baseline plasma levels of methylglyoxal hydroimidazolone, N∞-carboxymethyl lysine, N∞-carboxyethyl lysine (CEL), 3-deoxyglucosone hydroimidazolone and glyoxal hydroimidazolone (G-H1), 2-aminoadipic acid (2-AAA), and methionine sulfoxide were measured in a total of 411 participants, who underwent ultrasound assessment of carotid intima-media thickness (CIMT), and computed tomography scanning of coronary artery calcification (CAC) and abdominal aortic artery calcification (AAC) after an average of 10 years of follow-up. RESULTS In risk factor-adjustedmultivariable regressionmodels, G-H1was associated with the extent of CIMT and CAC. In addition, 2-AAA was strongly associated with the extent of CAC, and CEL was strongly associated with the extent of AAC. The combination of specific advanced glycation end products and oxidation products (G-H1 and 2-AAA) was strongly associated with all measures of subclinical atherosclerosis. CONCLUSIONS Specific advanced glycation end products and metabolic oxidation products are associated with the severity of subclinical atherosclerosis over the long term and may play an important role in the "negative metabolicmemory" of macrovascular complications in people with long-standing T2D.

AB - OBJECTIVE To determine whether plasma levels of advanced glycation end products and oxidation products play a role in the development of atherosclerosis in patients with type 2 diabetes (T2D) over nearly 10 years of the VA Diabetes Trial and Follow-up Study. RESEARCH DESIGN AND METHODS Baseline plasma levels of methylglyoxal hydroimidazolone, N∞-carboxymethyl lysine, N∞-carboxyethyl lysine (CEL), 3-deoxyglucosone hydroimidazolone and glyoxal hydroimidazolone (G-H1), 2-aminoadipic acid (2-AAA), and methionine sulfoxide were measured in a total of 411 participants, who underwent ultrasound assessment of carotid intima-media thickness (CIMT), and computed tomography scanning of coronary artery calcification (CAC) and abdominal aortic artery calcification (AAC) after an average of 10 years of follow-up. RESULTS In risk factor-adjustedmultivariable regressionmodels, G-H1was associated with the extent of CIMT and CAC. In addition, 2-AAA was strongly associated with the extent of CAC, and CEL was strongly associated with the extent of AAC. The combination of specific advanced glycation end products and oxidation products (G-H1 and 2-AAA) was strongly associated with all measures of subclinical atherosclerosis. CONCLUSIONS Specific advanced glycation end products and metabolic oxidation products are associated with the severity of subclinical atherosclerosis over the long term and may play an important role in the "negative metabolicmemory" of macrovascular complications in people with long-standing T2D.

UR - http://www.scopus.com/inward/record.url?scp=85019599007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019599007&partnerID=8YFLogxK

U2 - 10.2337/dc16-1875

DO - 10.2337/dc16-1875

M3 - Article

C2 - 28148544

AN - SCOPUS:85019599007

VL - 40

SP - 591

EP - 598

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 4

ER -